Biologics Manufacturing Market (By Modality, By Disease, By Manufacturing) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2025-2034

Biologics Manufacturing Market Size, Share, Report 2025-2034

The global biologics manufacturing market size stood at USD 33.52 billion in 2024 and is estimated to reach USD 39.25 billion in 2025. It is projected to hit USD 162.51 billion by 2034, registering a robust CAGR of 17.1% from 2025 to 2034. This strong market expansion is driven by the rising prevalence of chronic diseases, rapid advancements in monoclonal antibody engineering, increasing adoption of cell and gene therapies, and growing demand for targeted and personalized biologics. 

Key Pointers

• By region, North America held the largest market share of 42% in 2024.
• By region, Asia-Pacific is seen to grow at the fastest rate during the forecast period.
• By modality, the monoclonal antibodies segment dominated the market in 2024.
• By modality, the cell and gene therapies segment is expected to grow at the fastest rate during the forecast period.
• By disease type, the oncology segment led the market as of this year.
• By disease type, the infectious diseases segment is expected to grow at the fastest rate throughout the forecast years.
• By source, the mammalian segment was dominant in the market as of this year.
• By source, the microbial segment is expected to grow at the fastest rate.
• By manufacturing, in house segment dominated the market in 2024.
• By manufacturing, the outsourcing segment is seen to have the fastest growth rate.
  
  

Biologics Manufacturing Market Summary 

The biologics market has maintained strong momentum in biopharmaceutical innovation and targeted therapies. The market continues to reshape the treatment landscape across fields like oncology, immunology and rare diseases. Rising prevalence of chronic conditions, favorable reimbursement policies and accelerated regulatory pathways have driven widespread market adoption. As biologic pipelines continue to mature and diversify, pharmaceutical and biotech companies are focusing more on their investments in research, development and manufacturing capabilities, further expanding the landscape.

What is Biologics Manufacturing?

Biologic manufacturing is the process of producing medicine with the help of living organisms. Biotech and pharmaceutical companies make use of this approach in order to produce biologics like mAbs (monoclonal antibodies) or mRNA vaccines both at small and large scale, bringing several advantages over traditional small-molecule drug products.

Central practices in biomanufacturing consist of various stages of production, from upstream processes involving cell culturing and harvesting to downstream processes that focus on purification and formulation.

Report Scope of the Biologics Manufacturing Market

What are the Key Market Trends?

• Surge in Monoclonal Antibody Therapies: MABs continue to dominate the market, especially in fields like oncology and immunology, with new entrants leveraging advanced engineering techniques for enhanced efficacy.
• Rise of mRNA and RNA-based Therapeutics: The success of mRNA vaccines during the Covid-19 pandemic has led to increased investments into RNAi and antisense therapies targeting rare genetic diseases.
• Hybrid Manufacturing Models: Companies worldwide are increasingly adopting a blend of in-house and outsourced biologics manufacturing in order to optimize speed and scalability.
• Automation and AI in Biologic Manufacturing: Advanced manufacturing facilities are seen increasingly implementing AI and robotics for process optimization and quality assurance.
• Patient-centric Drug Delivery: Subcutaneous and self-administered biologic formulations are being developed in today’s market for chronic diseases and to enhance patient compliance.

What is the impact of AI in this field?

AI is revolutionizing the biologics manufacturing market in various domains like research, development and process development. AI enables a more precise and predictive approach to designing biologics. Digital twins are virtual models of bioreactors can simulate and optimize process parameters before any physical trials begin, which saves both time and resources. Machine learning is seen increasingly being applied to genomic, proteomic and metabolomic data as it deepens our understanding of how cells behave when producing a biologic, thus creating new ways to enhance productivity and quality. AI can also predict optimal media formulations and feeding strategies, replacing traditional trial-and-error work with data-driven accuracy.

Predictive maintenance systems are also a key component as they help to analyze sensor data to predict when equipment will require servicing, this prevents costly downtime and avoids production interruptions. AI also carries out continues monitoring can track critical quality attributes and flag anomalies earlier than manual methods, helping to ensure consistency across every batch. AI can also optimize production scheduling by using throughput data to maximize capacity and efficiency. Through all these factors, we can see how AI and Machine learning is changing the biologics manufacturing landscape, fostering innovation. 

Biologics Manufacturing Market Dynamics 

Driver

Rise of Chronic Diseases

Chronic diseases such as cancer, diabetes, and autoimmune disorders, require long-term management and are on the rise on a global scale. These diseases are often related to complex biological pathways, and traditional therapies cannot effectively manage them. Biologics are targeted to act upon these specific molecules or pathways, providing a more precise and effective approach towards treatment. Unlike traditional therapies, biologics are designed to work alongside with the body's normal processes to provide treatments complementary to the underlying causes of chronic diseases and are not just symptomatic. This targeted approach helps in enhancing therapeutic outcomes while also reducing the likelihood of adverse effects.

Additionally, these chronic disease burdens have put a greater emphasis on treatment options through innovation. Increasing awareness among physicians and patients regarding the benefits of biologics has increased market demand. 

Restraint 

High Costs 

Despite multiple prospects, the market does have its fair share of challenges that could potentially hinder its growth. The high cost of biologic therapies poses to be a significant restraint. This is because biologics often require intricate, living systems-based manufacturing, which necessitates advanced bioreactors, specialized personnel and stringent regulatory compliance. This can be a challenge in markets who are lacking universal healthcare or robust insurance systems. This disparity slows down market entry and development. 

Opportunity 

Innovation and Strong Regulatory Landscape 

The rising need for innovative and focused treatments is a key opportunity that is propelling the biologics manufacturing market. Targeted biologics, including monoclonal antibodies, antibody-drug conjugates and cell and gene therapies specifically target the molecular causes of any illnesses. These treatments are ideal for diseases such as cancer, autoimmune disorders and rare genetic diseases because of their precision. This increases treatment efficacy and reduces side effects. Pharmaceutical and biotechnology companies al, over the world are seen making significant investments in research pipelines to launch new advanced targeted biologics.

Regulatory bodies worldwide are establishing favorable pathways for their approval to support the adoption of biologics in clinical practice, opening up new avenues of opportunities. Targeted therapy success has also led to increased industry competition, compelling producers to increase production capacity, embrace cutting-edge bioprocessing technologies and form strategic alliances. As businesses continue to work to satisfy the growing demand for novel treatments, the market is witnessing accelerated growth. 

Regional Analysis in the Biologics Manufacturing Market

Why is North America dominating the market?

North America dominated the market as of this year in 2024. This is because the market’s ecosystem strong. The region also has a strong presence of cutting-edge startups like KBI Biopharma, Oxford Biomedicine and Aldevron. The region is also home to a well-developed healthcare infrastructure, has significant investment in research and development and also a favorable regulatory environment. This regulatory support, coupled with the availability of advanced medical facilities, solidifies the region’s leadership in the biologics market.

What are the advancements in Asia-Pacific?

Asia Pacific is expected to grow at the fastest rate during the forecast period. This growth is due to its large population and continuously expanding healthcare infrastructure. The region is also witnessing increasing collaboration between government agencies and biopharma companies are increasing research capabilities, which helps to accelerate drug development and commercialization. The market’s rapid expansion is also a result of supportive policies and a growing focus on innovation. 

Segmental Analysis 

Modality Analysis 

Which modality segment dominated the market in 2024?

The monoclonal antibodies segment dominated the market in 2024. Thid dominance is because they are widely used to treat infectious diseases, autoimmune disorders and cancer.  Strong clinical success rates, high specificity, and fewer side effects than compared to traditional therapies have fueled their widespread adoption. The increasing trend toward biosimilar mAbs and technological developments in bioprocessing further reinforces the segment's position.

The cell and gene therapies segment is expected to grow at the fastest rate during the forecast period. This growth is driven by the increasing number of FDA and EMA approvals, expanding clinical pipelines and strong investment inflows from biopharma companies and venture capital firms worldwide. This segment's growth is also attributed to the growing emphasis on personalized medicine and the expanding partnerships between CDMOs and biopharmaceutical companies.

Disease Category Analysis 

Which disease category led the market as of this year?

The Oncology segment led the market as of this year. This dominance is due to the high incidence of cancer worldwide and the ever increasingly need for targeted therapies. Advanced MABs have now become standard therapeutic tools in cancer treatment. Biologics are also critical in immuno-oncology, where they modulate immune response against tumor cells. With ongoing clinical trials in areas like CAR-T cell therapy and bispecific antibodies, oncology remains the most dominant and innovation-heavy segment.

The Infectious diseases segment is seen to be the fastest-growing segment throughout the forecast period. This segment’s growth was further propelled by the Covid-19 pandemic and has led to continued focus on vaccines and antivirals. The success of biologic vaccines like mRNA-based COVID-19 vaccines has prompted a surge in development activity for other viral threats like RSV and influenza. 

By Source Analysis

Which source segment dominated the market as of this year?

Mammalian cells dominated the market as of this year in 2024. The advantage of this segment is their ability to produce complex, human-like proteins with appropriate glycosylation. These cells are also suitable for large-scale commercial production and have a proven track record of regulatory approval. As companies continue to innovate in microbial production to improve yield and reduce costs, the demand for biologics will rise, solidifying this segment’s role.

Microbial systems are expected to be the fastest-growing segment, particularly when it comes to vaccines and recombinant proteins. These systems offer high-yield and cost-effective production along with simplified culture requirements. These platforms are also increasingly used for producing biosimilars and non-glycosylated proteins. Innovations in strain engineering and fermentation optimization are making microbial expression systems have enabled for more versatile and scalable options.

Manufacturing Analysis 

Which manufacturing segment held the largest market in 2024?

In-house manufacturing held the largest market share in 2024. This is because this segment enables better control and surveillance over the production process. Controlling the production process leads to better quality assurance, IP protection and seamless regulatory compliance. Various firms all over the world continue to invest in expanding their in-house capacities through advanced, cutting edge biomanufacturing campuses.

Outsourced manufacturing is estimated to be the fastest growing segment during the forecast years. particularly among emerging biotech companies and during clinical trial phases. This growth is driven by the increasing need for companies to reduce costs, enhance operational efficiency and lessen time-to-market. Outsourcing also provides a level of scalability, allowing companies to respond flexibly to the growing global demand. As biologics developers increasingly navigate the complexities, outsourcing remains a cost-effective and efficient solution for maintaining a competitive edge in the market. 

Recent Developments in the Biologics Manufacturing Market

• In September 2025, Precision Biologics Manufacturing, a New Horizon Medical Solutions (NHMS) company announced a groundbreaking for its manufacturing facility to develop advanced biologics technology and to bring MedTech jobs to Southern Nevada. Operated by Precision Biologics Manufacturing, the center will expand U.S.-based biologics production and create more than 200 to 300 healthcare-centric jobs in the Las Vegas Valley beginning in the second half of 2026. (Source: nwfdailynews) 
• In 2025, Abeona Therapeutics announced FDA approval for ZEVASKYN™ (pz-cel), making it the first and only autologous cell-based gene therapy for treating wounds in recessive dystrophic epidermolysis bullosa (RDEB) patients. This single-application treatment offers a significant breakthrough for the serious genetic skin disease, which currently has no cure. (Source: Abeona Therapeutics)

Top Key Players in the Biologics Manufacturing Market

• Samsung Biologics
• Amgen Inc.
• Novo Nordisk A/S
• AbbVie Inc.
• Sanofi
• Johnson & Johnson Services, Inc.
• Celltrion Healthcare Co., Ltd.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann La-Roche Ltd.
• Boehringer Ingelheim International GmbH
• Lonza

Segments Covered in the Report 

By Modality 

• Monoclonal Antibodies (mAbs)
• Biosimilar & Recombinant Proteins
• Vaccines (recombinant/mRNA/Viral)
• Cell & Gene Therapies
• RNA-based Therapeutics
• Others

By Disease 

• Oncology 
• Infectious Diseases 
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

By Source 

• Microbial
• Mammalian
• Others

By Manufacturing

• Outsourced
• In-house

By Region 

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa